| 1. |
- Awan, Ahmed Arslan Yousuf, et al.
(författare)
-
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline
- 2023
-
Ingår i: Annals of Internal Medicine. - : AMER COLL PHYSICIANS. - 0003-4819 .- 1539-3704. ; 176, s. 1648-1655
-
Tidskriftsartikel (refereegranskat)abstract
- Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease (CKD) is an update of the 2018 guideline from KDIGO.Methods: The KDIGO Work Group (WG) updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and used expert judgment to develop recommendations. New evidence led to updating of recommendations in the chapters on treatment of hepatitis C virus (HCV) infection in patients with CKD (Chapter 2), management of HCV infection before and after kidney transplant (Chapter 4), and diagnosis and management of kidney disease associated with HCV infection (Chapter 5). Recommendations in chapters on detection and evaluation of hepatitis C in CKD (Chapter 1) and prevention of HCV transmission in hemodialysis units (Chapter 3) were not updated because of an absence of significant new evidence.Recommendations: The 2022 updated guideline includes 43 graded recommendations and 20 ungraded recommendations, 7 of which are new or modified on the basis of the most recent evidence and consensus among the WG members. The updated guidelines recommend expanding treatment of hepatitis C with sofosbuvir-based regimens to patients with CKD glomerular filtration rate categories G4 and G5, including those receiving dialysis; expanding the donor pool for kidney transplant recipients by accepting HCV-positive kidneys regardless of the recipient's HCV status; and initiating direct-acting antiviral treatment of HCV-infected patients with clinical evidence of glomerulonephritis without requiring kidney biopsy. The update also addresses the use of immunosuppressive regimens in such patients.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Keshavarz, Mahmoud, 1985-, et al.
(författare)
-
Les passeurs, une aide nécessaire
- 2022
-
Ingår i: Atlas des migrations dans le monde. - : Armand Colin. - 9782200632823 ; , s. 114-115
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Partout où ils dessinent une frontière, vous pouvez construire un pont.Le poète afghan Najeeb Barwar, en jouant sur la métaphore, souligne ici une vérité que les discours qui parlent de murs et de systèmes de surveillance comme de frontières infranchissables ont tendance à dissimuler. En effet, ces murs ne sont pas immuables. Alors qu’ils semblent concrets et imposants, ils peuvent être contournés et transgressés. C’est cette leçon que les passeurs peuvent nous transmettre. La connaissance qu’ils ont des frontières est essentielle pour que les migrant·e·s puissent les contourner.Tout voyage nécessite une logistique complexe, une planification et des soutiens financiers. S’il se passe comme prévu, cette complexité demeurera invisible aux yeux de celles et ceux qui voyagent légalement. Beaucoup d’entre nous jouissent d’un statut juridique et économique qui nous évite d’être soumis·e·s à de telles exigences en matière de circulation. Nous pouvons payer pour différents services, par exemple une agence de voyage, des compagnies d’assurance, etc. qui s’occupent de la logistique et facilitent nos déplacements.C’est ce service essentiel que fournissent les passeurs en organisant la logistique de circulations bien plus complexes. Le recours constant aux passeurs, en dépit de leur condamnation par les États, est ainsi une indication à la fois du renforcement constant des contrôles frontaliers mais aussi de la capacité de ces agents à aider celles et ceux qui ont un accès limité à la mobilité…
|
|
| 6. |
- Manry, Jérémy, et al.
(författare)
-
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
- 2022
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 1091-6490. ; 119:21
-
Tidskriftsartikel (refereegranskat)abstract
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.
|
|
| 7. |
- Martin, Paul, et al.
(författare)
-
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
- 2022
-
Ingår i: Kidney International. - : ELSEVIER SCIENCE INC. - 0085-2538 .- 1523-1755. ; 102:6, s. 1228-1237
-
Tidskriftsartikel (refereegranskat)abstract
- Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.
|
|
| 8. |
|
|
| 9. |
- Tutkun, Murat, 1977, et al.
(författare)
-
Highly Time- and Space-Resolved Experiment on a High Reynolds Number Turbulent Boundary Layer
- 2007
-
Ingår i: ADVANCES IN TURBULENCE XI, Proceedings of the 11th EUROMECH European Turbulence Conference, June 25-28, 2007, Porto, Portugal, Editors: J.M.L.M. Palma and A.Silva Lopes Springer Proceedings in Physics 117, Springer, Heidelberg. - 9783540726036 ; , s. 346-348
-
Konferensbidrag (refereegranskat)
|
|
| 10. |
|
|
